Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 171-175

  Boone, Brian A ^a   Sabbaghian, Shirin ^a   Zenati, Mazen ^a   Marsh, J Wallis ^a   Moser, A James ^b   Zureikat, Amer H ^a   Singhi, Aatur D ^c   Zeh III, Herbert J ^a   Krasinskas, Alyssa M ^d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Surgery Beth Israel Deaconess ^*  (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

borderline resectable pancreatic cancer; portal vein resection; SMAD4

Indexed keywords

ANTINEOPLASTIC AGENT; SMAD4 PROTEIN;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAINING; SURGICAL APPROACH; SURVIVAL RATE;

BORDERLINE RESECTABLE PANCREATIC CANCER; PORTAL VEIN RESECTION; SMAD4;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; DECISION SUPPORT TECHNIQUES; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PILOT PROJECTS; PORTAL VEIN; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SMAD4 PROTEIN; STAINING AND LABELING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904071386     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23606     Document Type: Article

References (27)

1. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
2. Winter JM, Cameron JL, Campbell KA, et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210; discussion 1210-1191.
3. Wilentz RE, Su GH, Dai JL, et al.: Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000; 156: 37-43. (Pubitemid 30644436)
4. Iacobuzio-Donahue CA, Song J, Parmiagiani G, et al.: Missense mutations of MAD H4: Characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004; 10: 1597-1604. (Pubitemid 38435548)
5. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
6. Crane CH, Varadhachary GR, Yordy JS, et al.: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043.
7. Callery MP, Chang KJ, Fishman EK, et al.: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
8. Han SS, Park SJ, Kim SH, et al.: Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer. Pancreas 2012; 41: 102-106.
9. Murakami Y, Uemura K, Sudo T, et al.: Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J Surg Oncol 2013; 107: 414-421.
10. Riediger H, Makowiec F, Fischer E, et al.: Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006; 10: 1106-1115. (Pubitemid 44332981)
11. Tang D, Zhang JQ, Wang DR,: Long term results of pancreatectomy with portal-superior mesenteric vein resection for pancreatic carcinoma: a systematic review. Hepatogastroenterology 2011; 58: 623-631.
12. Fuhrman GM, Leach SD, Staley CA, et al.: Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996; 223: 154-162. (Pubitemid 26065208)
13. Zhou Y, Zhang Z, Liu Y, et al.: Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012; 36: 884-891.
14. Ramacciato G, Mercantini P, Petrucciani N, et al.: Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma ? Ann Surg Oncol 2009; 16: 817-825.
15. Castleberry AW, White RR, De La Fuente SG, et al.: The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol 2012; 19: 4068-4077.
16. Siriwardana HP, Siriwardena AK,: Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662-673. (Pubitemid 43886017)
17. Roder JD, Stein HJ, Siewert JR,: Carcinoma of the periampullary region: who benefits from portal vein resection ? Am J Surg 1996; 171: 170-174; discussion 174-175. (Pubitemid 126349891)
18. Launois B, Stasik C, Bardaxoglou E, et al.: Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer ? World J Surg 1999; 23: 926-929. (Pubitemid 29398475)
19. Navina S, McGrath K, Chennat J, et al.: Adequacy assessment of endoscopic ultrasound-guided-fine needle aspirations of pancreatic masses for theranostic studies: Optimization of current practices is warranted. Arch Pathol Lab Med in press.
20. Tseng JF, Raut CP, Lee JE, et al.: Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8: 935-949; discussion 949-950.
21. Katz MH, Pisters PW, Evans DB, et al.: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-846; discussion 846-838.
22. Jiang H, He C, Geng S, et al.: RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer. PLoS ONE 2012; 7: e42234.
23. Ottenhof NA, Morsink FH, Ten Kate F, et al.: Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr) 2012; 35: 119-126.
24. Shin SH, Kim SC, Hong SM, et al.: Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 2013; 42: 216-222.
25. Singh P, Srinivasan R, Wig JD,: SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2012; 41: 541-546.
26. Winter JM, Tang LH, Klimstra DS, et al.: Failure patterns in resected pancreas adenocarcinoma: Lack of predicted benefit to SMAD4 expression. Ann Surg 2013; 258: 331-335.
27. Bergmann F, Aulmann S, Wente MN, et al.: Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol 2006; 59: 580-584. (Pubitemid 43886040)